The case for adjuvant chemotherapy in pancreatic cancer

P Ghaneh; A Sultana; S Shore; Deborah Stocken; J Neoptolemos

doi:10.1016/j.bpg.2005.11.008

The case for adjuvant chemotherapy in pancreatic cancer

P Ghaneh, A Sultana, S Shore, Deborah Stocken, J Neoptolemos

Research output: Contribution to journal › Article

16 Citations (Scopus)

Abstract

Pancreatic cancer is a difficult cancer to treat effectively. Only a small proportion of patients are suitable for resection. The long-term survival following resection alone is between 10 and 18%. Adjuvant therapy aims to improve this outcome. There have been five fully reported adjuvant trials in pancreatic cancer. The largest study is the ESPAC-1 trial which demonstrated a significant survival benefit for 5-fluorouracil chemotherapy and no survival benefit for adjuvant chemoradiotherapy. A meta-analysis of these trials has confirmed the survival benefit for chemotherapy and thus adjuvant chemotherapy is recommended as the standard of care following pancreatic resection. There are further large studies which will also help to further define the optimum adjuvant chemotherapy in these patients.

Original language	English
Pages (from-to)	383-401
Number of pages	19
Journal	Best Practice & Research: Clinical Gastroenterology
Volume	20
DOIs	https://doi.org/10.1016/j.bpg.2005.11.008
Publication status	Published - 1 Apr 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bpg.2005.11.008

Cite this

@article{6fb17ca241c3409483c8a745332330ad,

title = "The case for adjuvant chemotherapy in pancreatic cancer",

abstract = "Pancreatic cancer is a difficult cancer to treat effectively. Only a small proportion of patients are suitable for resection. The long-term survival following resection alone is between 10 and 18%. Adjuvant therapy aims to improve this outcome. There have been five fully reported adjuvant trials in pancreatic cancer. The largest study is the ESPAC-1 trial which demonstrated a significant survival benefit for 5-fluorouracil chemotherapy and no survival benefit for adjuvant chemoradiotherapy. A meta-analysis of these trials has confirmed the survival benefit for chemotherapy and thus adjuvant chemotherapy is recommended as the standard of care following pancreatic resection. There are further large studies which will also help to further define the optimum adjuvant chemotherapy in these patients.",

author = "P Ghaneh and A Sultana and S Shore and Deborah Stocken and J Neoptolemos",

year = "2006",

month = apr,

day = "1",

doi = "10.1016/j.bpg.2005.11.008",

language = "English",

volume = "20",

pages = "383--401",

journal = "Best Practice & Research: Clinical Gastroenterology",

issn = "1521-6918",

publisher = "Elsevier",

}

TY - JOUR

T1 - The case for adjuvant chemotherapy in pancreatic cancer

AU - Ghaneh, P

AU - Sultana, A

AU - Shore, S

AU - Stocken, Deborah

AU - Neoptolemos, J

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Pancreatic cancer is a difficult cancer to treat effectively. Only a small proportion of patients are suitable for resection. The long-term survival following resection alone is between 10 and 18%. Adjuvant therapy aims to improve this outcome. There have been five fully reported adjuvant trials in pancreatic cancer. The largest study is the ESPAC-1 trial which demonstrated a significant survival benefit for 5-fluorouracil chemotherapy and no survival benefit for adjuvant chemoradiotherapy. A meta-analysis of these trials has confirmed the survival benefit for chemotherapy and thus adjuvant chemotherapy is recommended as the standard of care following pancreatic resection. There are further large studies which will also help to further define the optimum adjuvant chemotherapy in these patients.

AB - Pancreatic cancer is a difficult cancer to treat effectively. Only a small proportion of patients are suitable for resection. The long-term survival following resection alone is between 10 and 18%. Adjuvant therapy aims to improve this outcome. There have been five fully reported adjuvant trials in pancreatic cancer. The largest study is the ESPAC-1 trial which demonstrated a significant survival benefit for 5-fluorouracil chemotherapy and no survival benefit for adjuvant chemoradiotherapy. A meta-analysis of these trials has confirmed the survival benefit for chemotherapy and thus adjuvant chemotherapy is recommended as the standard of care following pancreatic resection. There are further large studies which will also help to further define the optimum adjuvant chemotherapy in these patients.

UR - http://www.scopus.com/inward/record.url?scp=33645028319&partnerID=8YFLogxK

U2 - 10.1016/j.bpg.2005.11.008

DO - 10.1016/j.bpg.2005.11.008

M3 - Article

C2 - 16549334

SN - 1521-6918

VL - 20

SP - 383

EP - 401

JO - Best Practice & Research: Clinical Gastroenterology

JF - Best Practice & Research: Clinical Gastroenterology

ER -

The case for adjuvant chemotherapy in pancreatic cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this